Cozzolino M et al. – The potential positive impact of the use of paricalcitol on diabetic nephropathy, cardiac disease, hypertension, and vascular calcification (VC) may open new paths in the fight against cardiovascular (CV) disease in chronic kidney disease (CKD) patients.
- In chronic kidney disease (CKD) patients, cardiovascular (CV) morbidity and mortality rate is higher than in the general population, because of frequently concomitant hypertension, peripheral vascular disease, heart failure, vascular calcification (VC), diabetes and mineral bone disease.
- Recently, another important factor associated to CV risk in CKD has been deeply investigated: vitamin D deficiency.
- Vitamin D Receptors (VDRs) are present in several systems and tissues and VDR activation is associated to positive effects, resulting in better blood pressure control and prevention of diabetic nephropathy.
- Unfortunately, the natural, non–selective vitamin D receptor activator (VDRA), calcitriol, is associated to higher serum calcium and phosphate levels, thus worsening CV risk in CKD.
- Recent data showed that the selective VDRA paricalcitol might have ameliorative CV effects.